Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical firm based in South San Francisco, is set to provide a comprehensive business update along with its financial results for the fourth quarter and full year 2025 on March 12, 2026, at 4:30 PM ET. Stakeholders can participate in the conference call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international participants. The event will also be available via a live webcast through the investor relations section of the Corvus website, with a replay accessible for 90 days post-event.

Corvus Pharmaceuticals is at the forefront of pioneering ITK (Interleukin-2-inducible T-cell kinase) inhibition as a novel therapeutic approach in the fields of immunotherapy and oncology. The company’s flagship investigational product, soquelitinib, is an oral small molecule designed to selectively inhibit ITK. Currently, soquelitinib is undergoing evaluation in a Phase 3 registration trial for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and in a Phase 1 trial for atopic dermatitis, showcasing the compound's versatility in tackling a range of immune-related diseases and certain cancers. In addition to soquelitinib, Corvus has a pipeline of other clinical candidates targeting various cancer indications, further solidifying its commitment to innovation in the biopharmaceutical landscape.

As Corvus prepares to share its latest developments and financial performance, analysts and investors are keen to gain insight into the company's strategic direction and potential market impacts. For further information, interested parties can contact Leiv Lea, Chief Financial Officer at Corvus Pharmaceuticals, or reach out to Sheryl Seapy at Real Chemistry for media inquiries.

As Corvus Pharmaceuticals prepares to release its fourth quarter and full year 2025 financial results on March 12, 2026, investors should approach the upcoming conference call with a keen focus on the company’s pipeline developments, particularly around its lead product candidate, soquelitinib. Given the company’s emphasis on ITK inhibition as a novel approach to treating various immune diseases and cancers, market participants will likely scrutinize any updates regarding clinical trial progress, especially since soquelitinib is in a registration Phase 3 trial for relapsed/refractory peripheral T-cell lymphoma (PTCL).

Investors should be aware that the Phase 3 trial's outcomes, if positive, could significantly enhance the company’s market valuation, considering the promising market potential for PTCL treatments. Thus, any mention of favorable trial results or interim data would be critical. On the flip side, if results are underwhelming or if any setbacks occur in the clinical trials, this could adversely affect investor sentiment.

Moreover, the company's progress in testing soquelitinib for other indications, such as atopic dermatitis, will be essential. An expansion of its pipeline could mitigate risks related to dependence on a single product and attract a broader base of investors.

Financially, it will be important to review the revenues, cash reserves, and expenditure outlined during the call. For clinical-stage companies like Corvus, a healthy cash runway is paramount for ongoing trials and operational sustainability. Investors should also look for guidance on anticipated milestones for 2026, which could provide insight into the company's strategic vision and operational pacing.

In this upcoming financial update, a balanced approach focusing on both potential growth from clinical achievements and the inherent risks of drug development will serve investors well.